^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GRN-1201

    i
    Other names: GRN-1201, GRN 1201
    Associations

    News

    Trials
    Company:
    BrightPath Biotherap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    over1year
    GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (clinicaltrials.gov)
    P2; Trial completion date: Oct 2023 --> Dec 2022 | Active, not recruiting --> Terminated; Recruitment rate too slow
    Trial completion date • Trial termination • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • GRN-1201
    over2years
    GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (clinicaltrials.gov)
    P2; Recruiting --> Active, not recruiting | N=64 --> 20 | Trial primary completion date: Oct 2022 --> Mar 2023
    Trial primary completion date • Enrollment change • Enrollment closed • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • HLA-A (Major Histocompatibility Complex, Class I, A) • IFNG (Interferon, gamma)
    |
    HLA-A*02
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab) • GRN-1201
    over4years
    GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC (clinicaltrials.gov)
    P2, N=64, Recruiting, BrightPath Biotherapeutics | Trial completion date: Mar 2021 --> Oct 2023 | Trial primary completion date: Mar 2020 --> Oct 2022
    Clinical • Trial completion date • Trial primary completion date • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    Keytruda (pembrolizumab) • GRN-1201